Amorphous drug transdermal systems, manufacturing methods, and stabilization

• US 20080226698A1
• Filed: 03/16/2007
• Published: 09/18/2008
• Est. Priority Date: 03/16/2007
• Status: Abandoned Application

• Current Assignee: Mylan Technologies Incorporated (Pfizer Inc.)
• Original Assignee: Mylan Technologies Incorporated (Pfizer Inc.)
• Inventors: Tang, Jiansheng, Deverich, Joseph M., Beste, Russell D., Miller, Kenneth J.
• Application Number:
  US11/725,159
• Publication Number:
  US 20080226698A1
• Time in Patent Office: Days
• US Class Current: 424/448
• CPC Class Codes: A61K 9/7053 obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
• CPC Class Codes: A61K 9/7069 obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/24 of the sex hormones
• CPC Class Codes: A61P 5/26 Androgens
• CPC Class Codes: A61P 5/30 Oestrogens
• CPC Class Codes: A61P 5/34 Gestagens

Abstract

The present invention refers to a transdermal delivery device comprising a backing layer, an adhesive matrix layer comprising a supersaturated concentration of an active agent substantially in amorphous form within the adhesive matrix, and a release liner. The present invention also refers to a method of preparing an adhesive matrix containing at least one supersaturated active agent substantially in amorphous form. Further, the present invention refers to a method to stabilize and a method to reestablish the meta-stable amorphous-drug transdermal system during its manufacturing, storing, shipping and handling process.

Claims

1. A transdermal delivery device comprising:

a) a backing layer,

b) an adhesive matrix layer comprising a supersaturated concentration of at least one active agent substantially in amorphous form within said adhesive matrix, and

c) a release liner.

2. The transdermal delivery device of claim 1, wherein said active agent is present in an amount of about 0.1% to about 50% by weight of said adhesive matrix.

3. The transdermal delivery device of claim 2, wherein said active agent is present in an amount of about 1% to about 20% by weight of said adhesive matrix.

4. The transdermal delivery device of claim 1, wherein the concentration of said active agent is from about 0.1% to about 10000% above the solubility of said active agent in said adhesive matrix.

5. The transdermal delivery device of claim 4, wherein the concentration of said active agent is from about 5% to about 5000% above the solubility of said active agent in said adhesive matrix.

6. The transdermal delivery device of claim 4, wherein the concentration of said active agent is from about 10% to about 1000% above the solubility of said active agent in said adhesive matrix.

7. The transdermal delivery device of claim 1, wherein said backing layer and said release liner are substantially non-crystallization inducing and free of crystallization nuclei or crystallization seeding particles.

8. The transdermal delivery device of claim 7, wherein said backing layer is selected from the group consisting of polyester films, polyethelene films, metal films, metalized polyester films, nylon films, ethylene vinyl acetate films laminated to a polyester, ethylene vinyl acetate films laminated to a metalized polyester, polyvinylidene fluoride films, silicone coated polyester films, silicone coated polyolefin films, and silicone coated ethyl vinyl acetate films.

9. The transdermal delivery device of claim 7, wherein said backing layer is the same size as said adhesive matrix layer.

10. The transdermal delivery device of claim 7, wherein said backing layer is larger than said adhesive matrix layer.

11. The transdermal delivery device of claim 7, wherein said release liner is selected from the group consisting of polyester liners, polyurethane liners, polyester liners with a silicone coating, polyurethane liners with a silicone coating, polyester liners with a fluorosilicone coating, polyurethane liners with a fluorosilicone coating, silicon coated polyester liners, silicon coated polyurethane liners, polyester liners with a fluoropolymer coating, and polyurethane liners with a fluoropolymer coating.

12. The transdermal delivery device of claim 11, wherein said release liner is larger than said adhesive matrix layer.

13. The transdermal delivery device of claim 12, wherein said release liner is about 0.1 mm to about 20 mm larger than said adhesive matrix layer.

14. The transdermal delivery device of claim 1, wherein said adhesive matrix layer comprises an adhesive material selected from the group consisting of polyisobutylene, polysiloxane, acrylic adhesives, natural and synthetic rubber adhesives, and mixtures thereof.

15. The transdermal delivery device of claim 14, wherein said adhesive material is present in an amount of from about 50% to about 99% by weight of said adhesive matrix layer.

16. The transdermal delivery device of claim 15, wherein said adhesive material is present in an amount of from about 60% to about 90% by weight of said adhesive matrix layer.

17. The transdermal delivery device of claim 1, wherein said adhesive matrix layer further comprises one or more tackifiers.

18. The transdermal delivery device of claim 17, wherein said one or more tackifiers is selected from the group consisting of polybutenes, mineral oils, and polysiloxanes.

19. The transdermal delivery device of claim 1, wherein said adhesive matrix layer further comprises one or more cohesive enhancers.

20. The transdermal delivery device of claim 19, wherein said one or more cohesive enhancers is selected from the group consisting of colloidal silicone dioxide, zinc oxide, polyvinylpyrrolidone, polyvinylpyrrolidone-co-vinylacetate, acrylate copolymers, crosspovidone, bentonites, clays, ethyl cellulose and mixtures thereof.

21. The transdermal delivery device of claim 1, wherein said adhesive matrix layer further comprises one or more flux enhancers.

22. The transdermal delivery device of claim 21, wherein said one or more flux enhancers is selected from the group consisting of propylene glycol, butylene glycol, dipropylene glycol, diethylene glycol, propyl palmitate, isopropyl palmitate, propyl myristate, pendadecanol, octadecanol, propylene glycol monoesters, polyethylene glycol monoesters and glycerol monoesters.

23. The transdermal delivery device of claim 1, further comprising a drug release regulating membrane layer and a reservoir layer.

24. The transdermal delivery device of claim 23, wherein at least one of said drug release regulating membrane layer and said reservoir layer contains said active agent.

25. The transdermal delivery device of claim 1, further comprising an overlay layer in communication with said backing layer.

26. The transdermal delivery device of claim 25, wherein said overlay layer is larger than said backing layer.

27. The transdermal delivery device of claim 26, wherein said overlay layer is about 0.01 mm to about 20 mm larger than said backing layer.

28. A transdermal delivery device comprising:

a) a backing layer,

b) an adhesive matrix layer comprising a supersaturated concentration of oxybutynin substantially in amorphous form within said adhesive matrix, and

c) a release liner.

29. The transdermal delivery device of claim 28, wherein said oxybutynin is present in an amount of about 0.1% to about 50% by weight of said adhesive matrix.

30. The transdermal delivery device of claim 29, wherein said oxybutynin is present in an amount of about 1% to about 20% by weight of said adhesive matrix.

31. The transdermal delivery device of claim 28, wherein the concentration of said oxybuytnin is from about 0.1% to about 10000% above the solubility of said oxybutynin in said adhesive matrix.

32. The transdermal delivery device of claim 31, wherein the concentration of said oxybutynin is from about 5% to about 5000% above the solubility of said oxybutynin in said adhesive matrix.

33. The transdermal delivery device of claim 31, wherein the concentration of said oxybutynin is from about 10% to about 1000% above the solubility of said oxybutynin in said adhesive matrix.

34. The transdermal delivery device of claim 28, wherein said backing layer and said release liner are substantially non-crystallization inducing and free of crystallization nuclei or crystallization seeding particles.

35. The transdermal delivery device of claim 34, wherein said backing layer is selected from the group consisting of polyester films, polyethelene films, metal films, metalized polyester films, nylon films, ethylene vinyl acetate films laminated to a polyester, ethylene vinyl acetate films laminated to a metalized polyester, polyvinylidene fluoride films, silicone coated polyester films, silicone coated polyolefin films, and silicone coated ethyl vinyl acetate films.

36. The transdermal delivery device of claim 34, wherein said backing layer is the same size as said adhesive matrix layer.

37. The transdermal delivery device of claim 34, wherein said backing layer is larger than said adhesive matrix layer.

38. The transdermal delivery device of claim 34, wherein said release liner is selected from the group consisting of polyester liners, polyurethane liners, polyester liners with a silicone coating, polyurethane liners with a silicone coating, polyester liners with a fluorosilicone coating, polyurethane liners with a fluorosilicone coating, silicon coated polyester liners, silicon coated polyurethane liners, polyester liners with a fluoropolymer coating, and polyurethane liners with a fluoropolymer coating.

39. The transdermal delivery device of claim 34, wherein said release liner is larger than said adhesive matrix layer.

40. The transdermal delivery device of claim 39, wherein said release liner is about 0.1 mm to about 20 mm larger than said adhesive matrix layer.

41. The transdermal delivery device of claim 28, wherein said adhesive matrix layer comprises an adhesive material selected from the group consisting of polyisobutylene, polysiloxane, acrylic adhesives, natural and synthetic rubber adhesives, and mixtures thereof.

42. The transdermal delivery device of claim 41, wherein said adhesive material is present in an amount of from about 50% to about 99% by weight of said adhesive matrix layer.

43. The transdermal delivery device of claim 42, wherein said adhesive material is present in an amount of from about 60% to about 90% by weight of said adhesive matrix layer.

44. The transdermal delivery device of claim 28, wherein said adhesive matrix layer further comprises one or more tackifiers.

45. The transdermal delivery device of claim 44, wherein said one or more tackifiers is selected from the group consisting of polybutenes, mineral oils, and polysiloxanes.

46. The transdermal delivery device of claim 28, wherein said adhesive matrix layer further comprises one or more cohesive enhancers.

47. The transdermal delivery device of claim 46, wherein said one or more cohesive enhancers is selected from the group consisting of colloidal silicone dioxide, zinc oxide, polyvinylpyrrolidone, polyvinylpyrrolidone-co-vinylacetate, acrylate copolymers, crosspovidone, bentonites, clays, ethyl cellulose and mixtures thereof.

48. The transdermal delivery device of claim 28, wherein said adhesive matrix layer further comprises one or more flux enhancers.

49. The transdermal delivery device of claim 48, wherein said one or more flux enhancers is selected from the group consisting of propylene glycol, butylene glycol, dipropylene glycol, diethylene glycol, propyl palmitate, isopropyl palmitate, propyl myristate, pendadecanol, pendadecalactone, octadecanol, propylene glycol monoesters, polyethylene glycol monoesters and glycerol monoesters.

50. The transdermal delivery device of claim 28, further comprising a drug release regulating membrane layer and a reservoir layer.

51. The transdermal delivery device of claim 50, wherein at least one of said drug release regulating membrane layer and said reservoir layer contains said oxybutynin.

52. The transdermal delivery device of claim 28, further comprising an overlay layer in communication with said backing layer.

53. The transdermal delivery device of claim 52, wherein said overlay layer is larger than said backing layer.

54. The transdermal delivery device of claim 53, wherein said overlay layer is about 0.01 mm to about 20 mm larger than said backing layer. I have temporarily renumbered this claim

55. A transdermal delivery device comprising:

a) a backing layer,

b) an adhesive matrix layer comprising a supersaturated concentration of an active agent substantially in amorphous form within said adhesive matrix, and

c) a release liner,

wherein said active agent is selected from the group consisting of piroxicam, fentanyl, naltrexone, scopolamine and a steroid.

56. The transdermal delivery device of claim 55, wherein said steroid is selected from the group consisting of estrogens, progestogens, testosterone, noregestrel, norethindrone acetate, medroxyprogesterone acetate, levonorgestrel, and norelgestromin.

57. The transdermal delivery device of claim 55, wherein said active agent is present in an amount of from about 0.1% to about 50% by weight of said adhesive matrix.

58. The transdermal delivery device of claim 55, wherein said active agent is present in an amount of from about 1% to about 20% by weight of said adhesive matrix.

59. The transdermal delivery device of claim 55, wherein the concentration of said active agent is from about 0.1% to about 10000% above the solubility of said active agent in said adhesive matrix.

60. The transdermal delivery device of claim 55, wherein the concentration of said active agent is from about 5% to about 5000% above the solubility of said active agent in said adhesive matrix.

61. The transdermal delivery device of claim 55, wherein the concentration of said active agent is from about 10% to about 1000% above the solubility of said active agent in said adhesive matrix.

62. The transdermal delivery device of claim 55, wherein said backing layer and said release liner are substantially non-crystallization inducing and free of crystallization nuclei or crystallization seeding particles.

63. The transdermal delivery device of claim 55, wherein said backing layer is selected from the group consisting of polyester films, polyethelene films, metal films, metalized polyester films, nylon films, ethylene vinyl acetate film laminated to a polyester, ethylene vinyl acetate films laminated to a metalized polyester, polyvinylidene fluoride films, silicone coated polyester films, silicone coated polyolefin films, and silicone coated ethyl vinyl acetate films.

64. The transdermal delivery device of claim 62, wherein said backing layer is the same size as said adhesive matrix layer.

65. The transdermal delivery device of claim 62, wherein said backing layer is larger than said adhesive matrix.

66. The transdermal delivery device of claim 62, wherein said release liner is selected from the group consisting of polyester liners, polyurethane liners, polyester liners with a silicone coating, polyurethane liners with a silicone coating, polyester liners with a fluorosilicone coating, polyurethane liners with a fluorosilicone coating, silicon coated polyester liners, silicon coated polyurethane liners, polyester liners with a fluoropolymer coating, and polyurethane liners with a fluoropolymer coating.

67. The transdermal delivery device of claim 62, wherein said release liner is larger than said adhesive matrix layer.

68. The transdermal delivery device of claim 67, wherein said release liner is about 0.1 mm to about 20 mm larger than said adhesive matrix layer.

69. The transdermal delivery device of claim 55, wherein said adhesive matrix layer comprises an adhesive material selected from the group consisting of polyisobutylene, polysiloxane, acrylic adhesives, natural and synthetic rubber adhesives, and mixtures thereof.

70. The transdermal delivery device of claim 69, wherein said adhesive material is present in an amount of from about 50% to about 99% by weight of said adhesive matrix layer.

71. The transdermal delivery device of claim 70, wherein said adhesive material is present in an amount of from about 60% to about 90% by weight of said adhesive matrix layer.

72. The transdermal delivery device of claim 55, wherein said adhesive matrix layer further comprises one or more tackifiers.

73. The transdermal delivery device of claim 72, wherein said one or more tackifiers is selected from the group consisting of polybutenes, mineral oils, and polysiloxanes.

74. The transdermal delivery device of claim 55, wherein said adhesive matrix layer further comprises one or more cohesive enhancers.

75. The transdermal delivery device of claim 74, wherein said one or more cohesive enhancers is selected from the group consisting of colloidal silicone dioxide, zinc oxide, polyvinylpyrrolidone, polyvinylpyrrolidone-co-vinylacetate, acrylate copolymers, and crosspovidone, bentonites, clays, ethyl cellulose and mixtures thereof.

76. The transdermal delivery device of claim 55, wherein said adhesive matrix layer further comprises one or more flux enhancers.

77. The transdermal delivery device of claim 76, wherein said one or more flux enhancers is selected from the group consisting of propylene glycol, butylene glycol, dipropylene glycol, diethylene glycol, propyl palmitate, isopropyl palmitate, propyl myristate, and glycerol monoesters.

78. The transdermal delivery device of claim 55, further comprising a drug release regulating membrane layer and a reservoir layer.

79. The transdermal delivery device of claim 78, wherein at least one of said drug release regulating membrane layer and said reservoir layer contains said active agent.

80. The transdermal delivery device of claim 55, further comprising an overlay layer in communication with said backing layer.

81. The transdermal delivery device of claim 80, wherein said overlay layer is larger than said backing layer.

82. The transdermal delivery device of claim 81, wherein said overlay layer is about 0.01 mm to about 20 mm larger than said backing layer.

83. A method of preparing an adhesive matrix containing at least one active agent that is supersaturated and present in amorphous form comprising:

a) dissolving said at least one active agent and an adhesive material in a solvent in an amount so as to provide said at least one active agent at a subsaturated concentration in an adhesive matrix solution,

b) casting said subsaturated active agent in said adhesive matrix solution to one of a release liner and a backing layer,

c) removing said solvent at a temperature which is at, below, or above the melting point of said at least one active agent to form a dry adhesive matrix in which said at least one active agent is in a supersaturated concentration, and

d) laminating the other of said release liner and said backing film to said supersaturated active agent in said dry adhesive matrix, so that said supersaturated active agent in said dry adhesive matrix is between said release liner and said backing layer.

84. The transdermal delivery device of claim 83, where said at least one active agent is selected from the group consisting of oxybutynin, piroxicam, fentanyl, naltrexone, scopolamine and a steroid.

85. The method of claim 83, wherein said release liner and said backing layer are non-crystallization inducing and free of crystallization nuclei or crystallization seeding particles.

86. The method of claim 83, wherein said supersaturated active agent in said adhesive matrix further comprises one or more additives which are dispersed as liquid or solid particles in said dry adhesive matrix.

87. The method of claim 86, wherein said one or more additives are selected from the group consisting of penetration enhancers, crystal growth inhibitors, tackifiers, cohesive enhancers, plasticizers, and antioxidants.

88. The method of claim 86, wherein said one or more additives are present in an amount of from about 1% to about 50% by weight of said adhesive matrix.

89. The method of claim 88, wherein said one or more adhesives are present in an amount of from about 2% to about 25% by weight of said adhesive matrix.

90. The method of claim 83, wherein said solvent is present in an amount of from about 1% to about 200% more than the amount necessary to solubilize said active agent and said adhesive.

91. The method of claim 83, wherein said solvent is selected from the group consisting of heptane, ethyl acetate, toluene, xylene, ethanol, and isopropanol.

92. The method of claim 84, wherein said active agent is present in an amount of from about 0.1% to about 50% by weight of said adhesive matrix layer.

93. The method of claim 92, wherein said active agent is present in an amount of from about 1% to about 20% by weight of said adhesive matrix layer.

94. The method of claim 83, wherein said adhesive matrix is present in an amount of from about 50% to about 99% by weight of said adhesive matrix layer.

95. The method of claim 94, wherein said adhesive matrix is present in an amount of from about 60% to about 90% by weight of said adhesive matrix layer.

96. A method of preparing an adhesive matrix containing at least one active agent that is supersaturated and present in amorphous form comprising:

a) admixing said at least one active agent with an adhesive matrix at a supersaturated concentration,

b) heating said supersaturated concentration of said at least one active agent in said adhesive matrix to a temperature which allows said at least one active agent to be completely dissolved and uniformly dispersed in said adhesive matrix to create a hot melt,

c) casting said hot melt to one of a release liner and a backing layer, at a predetermined temperature, and

d) laminating the other of said release liner and said backing layer to said hot melt, so that said hot melt is between said release liner and said backing layer.

97. The transdermal delivery device of claim 96, wherein said at least one active agent is selected from the group consisting of oxybutynin, piroxicam, fentanyl, naltrexone, scopolamine and a steroid.

98. The method of claim 96, wherein said release liner and said backing layer are non-crystallization inducing and free of crystallization nuclei or crystallization seeding particles.

99. The method of claim 96, wherein said hot melt further comprises one or more additives which are dispersed in said adhesive matrix.

100. The method of claim 99, wherein said one or more additives are selected from the group consisting of penetration enhancers, crystal growth inhibitors, tackifiers, cohesive enhancers, plasticizers, and antioxidants.

101. The method of claim 99, wherein said one or more additives are present in an amount of from about 1% to about 50% by weight of said adhesive matrix layer.

102. The method of claim 101, wherein said one or more adhesives are present in an amount of from about 2% to about 25% by weight of said adhesive matrix layer.

103. The method of claim 96, wherein said active agent is present in an amount of from about 0.1% to about 50% by weight of said adhesive matrix layer.

104. The method of claim 103, wherein said active agent is present in an amount of from about 1% to about 20% by weight of said adhesive matrix layer.

105. The method of claim 96, wherein said adhesive matrix is present in an amount of from about 50% to about 99% by weight of said adhesive matrix layer.

106. The method of claim 105, wherein said adhesive matrix is present in an amount of from about 60% to about 90% by weight of said adhesive matrix layer.

107. A method of removing crystallization nuclei and reestablishing the favored internal adhesive matrix environment of a transdermal drug delivery device having a backing layer, an adhesive matrix layer having a supersaturated concentration of an active agent substantially in the amorphous form within said adhesive matrix layer, and a release liner, said method comprising curing said transdermal delivery device.

108. The method of claim 107, wherein said active agent is selected from the group consisting of oxybutynin, piroxicam, fentanyl, naltrexone, scopolamine and a steroid.

109. The method of claim 107, wherein said curing comprises heating said transdermal delivery device to a temperature at which said active agent completely dissolves.

110. The method of claim 107, wherein said curing comprises heating said transdermal delivery device to a temperature about 20°

C. above the melting point of said active agent.

111. The method of claims 109 and 110, wherein said curing comprises subjecting said device to oven infrared beams.

112. The method of claim 111, wherein said curing is performed for a duration ranging from about 1 second to about 10 minutes.

113. The method of claim 112, wherein said duration ranges from about 3 seconds to about 5 minutes.

114. A method of storing and protecting a transdermal delivery device having a backing layer, an adhesive matrix layer comprising a supersaturated concentration of at least one active agent substantially in amorphous form within said adhesive matrix, and a release liner said method comprising packaging said transdermal delivery device in a pouch.

115. The method of claim 114, wherein said pouch is comprised of paper, polymer film, metal foil or combinations thereof.

116. The method of claim 114, wherein said pouch is the same size as said release liner.

117. The method of claim 114, wherein said pouch is larger than said release liner.

118. The method of claim 114, wherein said pouch is about 0.1 mm to about 20 mm larger than said release liner.